etoposide has been researched along with Malignant Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhebshi, H; Bakker, E; Demonacos, C; Guazzelli, A; Hussain, M; Krstic-Demonacos, M; Meysami, P; Mutti, L; Schwartz, JM; Tian, K | 1 |
| Arslan, D; Bozcuk, H; Coskun, HS; Goksu, SS; Gunduz, S; Mutlu, H; Ozdogan, M; Savas, B; Tatli, AM; Uysal, M | 1 |
2 other study(ies) available for etoposide and Malignant Mesothelioma
| Article | Year |
|---|---|
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Models, Biological; Neoplasm Staging; Pleural Neoplasms; Proportional Hazards Models; Transcriptome; Tumor Suppressor Protein p53; Wound Healing | 2018 |
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |